ERYC 125 Drug Patent Profile
✉ Email this page to a colleague
When do Eryc 125 patents expire, and what generic alternatives are available?
Eryc 125 is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in ERYC 125 is erythromycin. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eryc 125
A generic version of ERYC 125 was approved as erythromycin by TORRENT on July 6th, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ERYC 125?
- What are the global sales for ERYC 125?
- What is Average Wholesale Price for ERYC 125?
Summary for ERYC 125
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 108 |
| Patent Applications: | 3,890 |
| DailyMed Link: | ERYC 125 at DailyMed |
US Patents and Regulatory Information for ERYC 125
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | ERYC 125 | erythromycin | CAPSULE, DELAYED REL PELLETS;ORAL | 062648-001 | Oct 24, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
